Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RITZ: rituximab plus zanubrutinib versus rituximab alone in previously untreated symptomatic splenic marginal zone lymphoma
2023-503755-10-00Phase 3Authorised
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial in splenic marginal zone lymphoma (SMZL) comparing Rituximab plus zanubrutinib with Rituximab monotherapy (2 arms). Primary endpoint: Progression-free survival rate at 3 years. Planned start Apr 2024; status: authorised.
02
Drugs
zanubrutinibrituximab
03
Conditions
splenic marginal zone lymphoma (SMZL)
Beyond the preview
Go deeper on 2023-503755-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503755-10-00.